Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — B. Riley FBR Investor Conference 2019
15 slides from Vivani Medical's conference presentation, May 23, 2019
Slide 1: Discover Life in a New Light
Second Sight Medical Products, Inc. (NASDAQ: EYES) Discover Life in a New Light® B. Riley FBR Investor Conference May 23, 2019 Ex 99.1
Slide 2: Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All st
Slide 3: Two Breakthrough Technologies
Two Breakthrough Technologies Argus® II Retinal Prosthesis Legacy Technology Development Platform First and only FDA approved retinal prosthesis 20+ years and ~$200M invested to develop underlying technology and commercialize Durable array design (10+ years) and proprietary software algorithms with
Slide 4: Orion Visual Cortical Prosthesis Overview
Orion is a investigational visual cortical prosthesis that induces visual perception in blind individuals Orion Visual Cortical Prosthesis Overview Video Link: https://youtu.be/yiaKNmUIcqs
Slide 5: Orion: Breakthrough Device with Potential to Treat Virtually All Forms of Blindness
Approximately current addressable market in the U.S. Orion®: Breakthrough Device with Potential to Treat Virtually All Forms of Blindness U.S. 70,000+ 500,000+ Addressable market With bare light or no light perception Legally blind due to glaucoma, diabetic retinopathy, optic nerve disease, eye trau
Slide 6: Encouraging Orion Interim Study Results
Encouraging Orion® Interim Study Results Conducting a six subject feasibility study at Ronald Reagan UCLA Medical Center and Baylor College of Medicine Six subjects cleared for home use Initial results from our testing include the following: Stimulation parameters are within expected ranges and fiel
Slide 7: Growth Strategy Centered on Orion
Growth Strategy Centered on Orion® Orion Argus Research Execute Orion clinical and R&D programs Positive interim results of six subject U.S. Early Feasibility Study at UCLA and Baylor R&D to iterate cortical prosthesis and external components in preparation for pivotal trial Orion designated FDA Bre
Slide 8: Orion Extends our Leadership Position in Artificial Vision
Orion® Extends our Leadership Position in Artificial Vision Established technology with 10+ years proven implant durability Proprietary algorithms for artificial vision Over 85 issued U.S. patents for Orion Orion leverages Argus II technology platform Argus is an established therapy in over a dozen
Slide 9: Research Projects to Enhance User Experience
Research Projects to Enhance User Experience Eye Tracking Move the implant field of view in conjunction with the movement of the user’s eyes Thermal Imaging Infrared imaging would allow users to visualize warm objects such as people in a room Depth-Based Decluttering Allow users to filter out object
Slide 10: Pipeline with Clear Path to Innovations
Pipeline with Clear Path to Innovations Argus II: Commercial Orion: Early Feasibility Study Argus 2s: Clinical Validation Study Research CLINICAL TRIALS FDA APPROVAL COMMERCIAL Assistive Technologies Retinitis Pigmentosa Eye Trauma/Injury Glaucoma Diabetic Retinopathy Optic Nerve Disease Enhancement
Slide 11: Key Drivers of Shareholder Value in 2019
Key Drivers of Shareholder Value in 2019 Orion Agreement w/ FDA for Orion Clinical & Regulatory Pathway Maximize Argus II ROI Orion Early Feasibility Study Data (6 and 12 Mo) Orion Early Feasibility Study and release interim data from first six subjects at six months and one year Agreement on pivota
Slide 12: Select Financial Data
Select Financial Data 1) Non-GAAP adjusted net loss excludes non-cash expenses including stock-based compensation and reserve for excess inventory. (USD $ in thousands) Q1 2019 Q1 2018 Argus® II Implants 10 16 Revenue $1,128 $976 Gross Profit $397 $308 Net Loss $(9,700) $(9,753) Non-GAAP Adjusted Ne
Slide 13: Experienced Leadership Team
Experienced Leadership Team Will McGuire President & CEO 20+ years experience in medical device industry Extensive leadership experience across both public and private companies Most recently as President of Americas Commercial for Volcano Corporation (acquired by Phillips for $1.2B in 2015). John B
Slide 14: Second Sight Investment Highlights
Second Sight Investment Highlights Orion is a large market opportunity that’s more than 50x the current RP market Potential to treat nearly all forms of blindness including diabetic retinopathy, glaucoma, optic nerve disease and eye injury Six subject feasibility study at UCLA and Baylor underway wi
Slide 15: Contacts
Contacts Second Sight Medical Products, Inc. 12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818-833-5000 www.secondsight.com Will McGuire President & CEO Direct: 818-833-5040 wmcguire@secondsight.com Institutional Investor Relations Lisa Wilson President In-Site Communications, Inc. Direct
Second Sight Medical Products — B. Riley FBR Investor Conference 2019 on 6ix